Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

Global Biosimilar Testing and Development Services Market is valued approximately at USD 2.80 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.1% over the forecast ...

The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.

FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...

“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.